Engineered immune cells take aim at tough blood cancers
NCT ID NCT07162571
Summary
This early-stage trial is testing a new cell therapy for adults with leukemia or lymphoma that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back. The study will first check if the treatment is safe and then measure how well it shrinks or eliminates the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology
Minsk, 220087, Belarus
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.